$IBOGF-Average VolumeUniversal Ibogaine Inc. is seen to be doing well in the OTC market with its ticker symbol $IBOGF. The average volume in the last 30 days is recorded to be above $8K.
Smallcapstocks
$IBO Stock AnalysisUniversal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $145K in the last 3 months. During the last 10 days the average volume remained $112K with $190M share outstanding.
$IBOGF market capitalization at the apex, investors overwhelmed $IBO over the years have maintained a solid and supple market cap, currently the company’s market capitalization is valued over $7.57M and is mounting effectively
Universal Ibogaine Market SummaryUniversal Ibogaine Inc. is a Canadian Life science Company trading at OTC with ticker symbol $IBOGF currently sits at $0.0376 with volume around 10K+.
$HMTXF Market Opening Value Hemostemix is a publicly traded biotechnology company listed on OTC. Today it has recorded a market opening price of $0.2151.
$IBO Stock Analysis GraphUniversal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $172K+ in the last 3 months. The average volume of the company in the last 10 days is $97K with $190.16M share outstanding. The stock price when the market opened was $0.05.
$IBO shares trading unobstructed on the TSX-V$IBO is gliding swiftly on the TSX-V Index, the shares are trading currently at $0.05 which might get doubled in the upcoming days or week maximum.
$HEM- Market Opening ValueHemostemix Inc. is a publicly traded biotechnology company listed on TSX-V marked with an opening of $0.285.
Universal Ibogaine Delivering Excellence The Company newly reported that its common shares, coined as "JC4", have been accepted for trade on the Frankfurt Stock Exchange, or Boerse Frankfurt. In Canada, UI will keep trading on the TSX Venture Exchange under the ticker IBO and on the OTCQB under the stock symbol IBOGF.
$IBOGF accord with blue digital media calls for added benefitsBlue Digital will be paid USD 27,000 for a three-month commitment beginning June 13, 2022. Additionally, Blue Digital will get 450,000 company's stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a three-year term, and one-third vesting at the conclusion of each month of service.
Blue digital media to highlight $IBO narrativeThe UI story will be distributed through numerous platforms and audiences by Blue Digital. The expected outcome is increased knowledge of UI's plans to conduct research into the use of ibogaine as part of a continuum of care for opioid addiction and other addictions.
$IBO an investor’s alluring stock investment$IBO has been elastic through the ebbs and flows of the market and have always maintained a tight toe hold in the Canadian venture exchange, its consistency to this day is what intrigues investors globally, the shares are trading at $0.05 with no such recorded loss
$IBOGF- 30 day Average Volume
The volume of $IBOGF is increasing day by day. In the last 30 days the average volume of $IBOGF has been recorded to be $4.42K.
Universal Ibogaine in the Virtual Growth ConferenceUniversal Ibogaine Inc. is going to participate in the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest.
$IBOGF’s Addiction treatmentUniversal Ibogaine Inc. is a life science company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model through a planned Canadian Clinical trial.
$IBO contract with blue digital media dictates further benefitsBlue Digital will be paid USD 27,000 for a three-month commitment beginning June 13, 2022. Additionally, Blue Digital will get 450,000 company's stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a three-year term, and one-third vesting at the conclusion of each month of service.
Recent offering made by $HMTXF only for existing shareholdersThe offering constituting the private non-brokered placement of 15 Million units is only available to existing shareholders of the company, who as of the closing of business on May 16, 2022 hold common shares of Hemostemix
$HEM with a breath taking stock performance on TSX-V$HEM is currently trading on the TSX-V effortlessly at $0.28 with no such loss percentage recorded yet and is expected to rise significantly in the upcoming week effectively.
$HEM market cap mounts to $19.7 Million strong$HEM have developed and established a firm market cap which has been on the rise steadily since the listing of the stock on TSX-V, currently the cap valuation is $19.773 Million.
Hemostemix Inc. interest payment on convertible debentureHemostemix Inc. announced that it will pay interest of $84,804.40 by issuing 446,339 Common Shares, using the March 2, 2022 closing price of $0.19 per share, to the convertible debenture holder in satisfaction of interest due on the outstanding principal amount of $2,500,000 for the period from inception, June 11, 2021, to December 31, 2021.
